419 related articles for article (PubMed ID: 29509927)
41. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
Chaparro M; Garre A; Ricart E; Iborra M; Mesonero F; Vera I; Riestra S; García-Sánchez V; Luisa De Castro M; Martin-Cardona A; Aldeguer X; Mínguez M; de-Acosta MB; Rivero M; Muñoz F; Andreu M; Bargalló A; González-Muñoza C; Pérez Calle JL; García-Sepulcre MF; Bermejo F; Huguet JM; Cabriada JL; Gutiérrez A; Mañosa M; Villoria A; Carbajo AY; Lorente R; García-López S; Piqueras M; Hinojosa E; Arajol C; Sicilia B; Conesa AM; Sainz E; Almela P; Llaó J; Roncero O; Camo P; Taxonera C; Domselaar MV; Pajares R; Legido J; Madrigal R; Lucendo AJ; Alcaín G; Doménech E; Gisbert JP;
Aliment Pharmacol Ther; 2018 Oct; 48(8):839-851. PubMed ID: 30281832
[TBL] [Abstract][Full Text] [Related]
42. Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease.
Yung DE; Horesh N; Lightner AL; Ben-Horin S; Eliakim R; Koulaouzidis A; Kopylov U
Inflamm Bowel Dis; 2018 Oct; 24(11):2327-2338. PubMed ID: 29788385
[TBL] [Abstract][Full Text] [Related]
43. Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis.
Novello M; Stocchi L; Holubar S; Shawki S; Lipman J; Gorgun E; Hull T; Steele SR
Int J Colorectal Dis; 2019 Mar; 34(3):451-457. PubMed ID: 30535559
[TBL] [Abstract][Full Text] [Related]
44. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study.
Bor R; Fábián A; Matuz M; Szepes Z; Farkas K; Miheller P; Szamosi T; Vincze Á; Rutka M; Szántó K; Bálint A; Nagy F; Milassin Á; Tóth T; Zsigmond F; Bajor J; Müllner K; Lakner L; Papp M; Salamon Á; Horváth G; Sarang K; Schäfer E; Sarlós P; Palatka K; Molnár T
Expert Opin Biol Ther; 2020 Feb; 20(2):205-213. PubMed ID: 31782939
[No Abstract] [Full Text] [Related]
45. Vedolizumab as a rescue therapy for patients with medically refractory Crohn's disease.
Crowell KT; Tinsley A; Williams ED; Coates MD; Bobb A; Koltun WA; Messaris E
Colorectal Dis; 2018 Oct; 20(10):905-912. PubMed ID: 29673053
[TBL] [Abstract][Full Text] [Related]
46. Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects.
Pijls PA; Gilissen LP
Dig Liver Dis; 2016 Nov; 48(11):1391-1393. PubMed ID: 27639825
[TBL] [Abstract][Full Text] [Related]
47. Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center.
Dragoni G; Bagnoli S; Le Grazie M; Campani C; Rogai F; Manetti N; Bensi C; Macrì G; Galli A; Milla M
J Dig Dis; 2019 May; 20(5):235-242. PubMed ID: 30927309
[TBL] [Abstract][Full Text] [Related]
48. Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor α Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience.
Pabla BS; Alex Wiles C; Slaughter JC; Scoville EA; Dalal RL; Beaulieu DB; Schwartz DA; Horst SN
Dig Dis Sci; 2022 Jul; 67(7):3129-3137. PubMed ID: 34268660
[TBL] [Abstract][Full Text] [Related]
49. VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY.
Perin RL; Damião AOMC; Flores C; Ludvig JC; Magro DO; Miranda EF; Moraes AC; Nones RB; Teixeira FV; Zeroncio M; Kotze PG
Arq Gastroenterol; 2019; 56(3):312-317. PubMed ID: 31633731
[TBL] [Abstract][Full Text] [Related]
50. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
Biemans VBC; van der Woude CJ; Dijkstra G; van der Meulen-de Jong AE; Löwenberg M; de Boer NK; Oldenburg B; Srivastava N; Jansen JM; Bodelier AGL; West RL; de Vries AC; Haans JJL; de Jong D; Hoentjen F; Pierik MJ;
Aliment Pharmacol Ther; 2020 Jul; 52(1):123-134. PubMed ID: 32441396
[TBL] [Abstract][Full Text] [Related]
51. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study.
Adar T; Faleck D; Sasidharan S; Cushing K; Borren NZ; Nalagatla N; Ungaro R; Sy W; Owen SC; Patel A; Cohen BL; Ananthakrishnan AN
Aliment Pharmacol Ther; 2019 Apr; 49(7):873-879. PubMed ID: 30773667
[TBL] [Abstract][Full Text] [Related]
52. A product review of vedolizumab in inflammatory bowel disease.
Battat R; Dulai PS; Jairath V; Vande Casteele N
Hum Vaccin Immunother; 2019; 15(10):2482-2490. PubMed ID: 30897022
[TBL] [Abstract][Full Text] [Related]
53. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease.
Waterman M; Xu W; Dinani A; Steinhart AH; Croitoru K; Nguyen GC; McLeod RS; Greenberg GR; Cohen Z; Silverberg MS
Gut; 2013 Mar; 62(3):387-94. PubMed ID: 22619367
[TBL] [Abstract][Full Text] [Related]
54. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
[TBL] [Abstract][Full Text] [Related]
55. Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience.
Shwaartz C; Fields AC; Sobrero M; Cohen BD; Divino CM
J Gastrointest Surg; 2016 Sep; 20(9):1636-42. PubMed ID: 27405310
[TBL] [Abstract][Full Text] [Related]
56. Preoperative chemotherapy and corticosteroids: independent predictors of cranial surgical-site infections.
Lieber BA; Appelboom G; Taylor BE; Lowy FD; Bruce EM; Sonabend AM; Kellner C; Connolly ES; Bruce JN
J Neurosurg; 2016 Jul; 125(1):187-95. PubMed ID: 26544775
[TBL] [Abstract][Full Text] [Related]
57. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease.
Armuzzi A; Gionchetti P; Daperno M; Danese S; Orlando A; Lia Scribano M; Vecchi M; Rizzello F;
Dig Liver Dis; 2016 Apr; 48(4):360-70. PubMed ID: 26821929
[TBL] [Abstract][Full Text] [Related]
58. Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients.
Lightner AL; McKenna NP; Alsughayer A; Loftus EV; Raffals LE; Faubion WA; Moir C
J Pediatr Surg; 2019 Oct; 54(10):2162-2165. PubMed ID: 30773391
[TBL] [Abstract][Full Text] [Related]
59. Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience.
Rizzo G; Armuzzi A; Pugliese D; Verbo A; Papa A; Mattana C; Rapaccini GL; Guidi L; Coco C
Int J Colorectal Dis; 2011 Nov; 26(11):1435-44. PubMed ID: 21594668
[TBL] [Abstract][Full Text] [Related]
60. Hypoalbuminaemia, Not Biologic Exposure, Is Associated with Postoperative Complications in Crohn's Disease Patients Undergoing Ileocolic Resection.
Shah RS; Bachour S; Jia X; Holubar SD; Hull TL; Achkar JP; Philpott J; Qazi T; Rieder F; Cohen BL; Regueiro MD; Lightner AL; Click BH
J Crohns Colitis; 2021 Jul; 15(7):1142-1151. PubMed ID: 33388775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
